🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Wow, Dino in action. Love it.

Listen in as expert oncologists expand on contemporary sequencing with CD20xCD3 bispecific antibodies in R/R diffuse-large B-cell #lymphoma. Matt Lunning D.O. L. Elizabeth Budde, M.D., Ph.D. Leo Gordon Frederick L. Locke #oncology #hematology onclive.com/view/contempor…

Three patients of mine treated with Mosun at 1.6mg q3weeks back in 2016, have remained in remission. Mosun was approved in 12.2022. The GO29781 clinical trial gave them access to “tomorrow’s medicine” 6 years earlier.

Endorse. Endorse. Endorse.

Great to see the expansion of bispeciifc T cell engager into treating mantle cell lymphoma.

A wonderful milestone CELLebration of treating 1600+ IEC/CAR T patients at City of Hope. Humble to work with so many fabulous staff, colleagues and leaders. Edward S. Kim, MD, MBA, FACP, FASCO Marcel van den Brink City of Hope

Transformative work and new standard of care for newly diagnosed HL, led by our very own Alex Herrera City of Hope

Watch experts @MatthewLunning, DO, FACP, of University of Nebraska Medical Center L. Elizabeth Budde, M.D., Ph.D., MD, PhD of City of Hope, Leo Gordon, MD of @LurieCancerCenter Frederick L. Locke, MD of Moffitt Cancer Center discuss the current treatment landscape for bispecific antibodies and CAR T in R/R #DLBCL onclive.com/view/dispariti…

Thank you Lymphoma Hub for a great interview. 3+ year follow up on mosunetuzumab in pts with R/R follicular lymphoma. 71% CR pts remained in CR; DOR 56%; 3 yr PFS 43%. Gratifying to see trials evaluating Mosun in early lines coming to fruition. Look forward to ASH2024.

No words to describe this moment. Dodgers won the 8th world series 4:0!

Very excited that we have successfully implemented hybrid interstitial brachytherapy at OC | Radiation Oncology! A critical step to providing top-level brachytherapy for gynecological malignancies in Orange County #radonc #thisisbrachytherapy

Great advice.

The past few days have been tough and emotionally draining. So blessed to work with many amazing colleagues City of Hope in this trying time.

This is really cool.

This is incredible. Will certainly try it out.

Very proud that Murali Janakiram has done a phenomenal job leading the MM Bispecific OP efforts at COH and sharing his expertise with ACCC and the community.

45 of the 55 participating sites in the MorningSun study are community sites; making this study truly meaningful and wonderful. Kudos to all the treatment physicians who took the extra time supporting and conducting clinical research.

ICML 2025: sunny in Lugano. SUNMO is shining. The phase 3 trial Mosun-Pola vs RGEMOX met its dual primary endpoints. Mosun-Pola is an effective and safe out patient immune-based regimen for r/r LBCL. A regimen with great potential to benefit patients in the community.

ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.

I am jealous of the speed.